These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3678329)

  • 41. Mathematical analysis of cancer chemotherapy: the effects of chemotherapeutic agents on the cell cycle traverse.
    Chuang SN; Soong TT
    Bull Math Biol; 1978; 40(4):499-512. PubMed ID: 678695
    [No Abstract]   [Full Text] [Related]  

  • 42. Tumour resistance to cisplatin: a modelling approach.
    Marcu L; Bezak E; Olver I; van Doorn T
    Phys Med Biol; 2005 Jan; 50(1):93-102. PubMed ID: 15715425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity.
    Costa MI; Boldrini JL; Bassanezi RC
    Math Biosci; 1995 Feb; 125(2):211-28. PubMed ID: 7881195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prevention of resistance to chemotherapy in the therapeutic strategy for cancer].
    Droz JP
    Bull Cancer; 1994 Dec; 81 Suppl 2():91s-94s. PubMed ID: 7727869
    [No Abstract]   [Full Text] [Related]  

  • 45. Cell population kinetics - experimental methods and their in vivo relevance for human cancer chemotherapy.
    Hill BT; Whelan RD; Rupniak HT; Price LA
    Arch Geschwulstforsch; 1981; 51(1):103-10. PubMed ID: 7259432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experimental chemotherapy and concepts related to the cell cycle.
    Tannock IF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1986 Feb; 49(2):335-55. PubMed ID: 3510996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On the importance of sensitivity to the dose-effect relationship in chemotherapy.
    Jakobsen A; Mortensen LS
    Acta Oncol; 1997; 36(4):375-81. PubMed ID: 9247097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.
    Eisenberg MC; Jain HV
    J Theor Biol; 2017 Oct; 431():63-78. PubMed ID: 28733187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A mathematical model for M-phase specific chemotherapy including the G0-phase and immunoresponse.
    Liu W; Hillen T; Freedman HI
    Math Biosci Eng; 2007 Apr; 4(2):239-59. PubMed ID: 17658926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms to improve chemotherapy effectiveness.
    Young RC
    Cancer; 1990 Feb; 65(3 Suppl):815-22. PubMed ID: 2406004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal control for a cancer chemotherapy problem with general growth and loss functions.
    Murray JM
    Math Biosci; 1990 Mar; 98(2):273-87. PubMed ID: 2134507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.
    Ribba B; Saut O; Colin T; Bresch D; Grenier E; Boissel JP
    J Theor Biol; 2006 Dec; 243(4):532-41. PubMed ID: 16930628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of cell kinetics in cancer chemotherapy.
    Valeriote FA; Edelstein MB
    Semin Oncol; 1977 Jun; 4(2):217-26. PubMed ID: 327554
    [No Abstract]   [Full Text] [Related]  

  • 54. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell cycle kinetics and mitotically linked chemotherapy.
    Mendelsohn ML
    Cancer Res; 1969 Dec; 29(12):2390-3. PubMed ID: 5369686
    [No Abstract]   [Full Text] [Related]  

  • 56. [Therapeutic failure of antineoplastic agents. Extracellular and cellular causes].
    Hofsli E
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):37-40. PubMed ID: 2000585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume.
    Gregory WM; Reznek RH; Hallett M; Slevin ML
    Br J Cancer; 1990 Oct; 62(4):671-5. PubMed ID: 2223589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
    West J; Newton PK
    Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A model for metastases formation.
    Markovitch S
    Int J Biomed Comput; 1993 Jan; 32(1):19-33. PubMed ID: 8425750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1979; 63(11-12):1727-33. PubMed ID: 526911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.